Morning Seminar April 14, 2009

Leukemia. 2007 Nov;21(11):2258-63.
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group.
Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, Kosaka Y, Oda T, Oda M, Hayashi Y, Eguchi M, Horibe K, Nakahata T, Mizutani S, Ishii E.

Blood. 2004 Dec 1;104(12):3527-34.
Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation.
Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T, Hayashi Y, Ohta S, Moritake H, Oda M, Nagatoshi Y, Kigasawa H, Ishida Y, Ohara A, Hanada R, Sako M, Sato T, Mizutani S, Horibe K, Ishii E.

Blood. 2006 Feb 1;107(3):1238-9.
KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia.
Triplett B, Handgretinger R, Pui CH, Leung W.